VAERS reports by lot

Merck HPV lot J009788: VAERS reports

91 VAERS reports list lot J009788 as a Merck HPV vaccine, received between 2013-11-21 and 2017-09-08. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
91
Reports
16%
Marked serious
0
With a death outcome
27
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
Neurological3425%
Cardiac / Cardiovascular2518%
General / Systemic (non-local)2014%
Gastrointestinal1612%
Dermatological (non-injection-site)139%
Musculoskeletal97%
Injection-site / Local reaction97%
Allergic / Anaphylactic54%
Thrombotic / Hematological32%
Respiratory21%
Autoimmune / Immune-mediated11%
Psychiatric / Neuropsychiatric11%

Where reports came from

U.S. state of the reporter, where given (top 12).

California21
Pennsylvania14
Florida4
Texas3
Massachusetts3
New Jersey2
Colorado2
Arizona1
Indiana1
Washington1
District of Columbia1
Utah1

Reports by month received

2013-112
2013-121
2014-011
2014-023
2014-032
2014-041
2014-051
2014-068
2014-0711
2014-088
2014-0911
2014-102
2014-1111
2015-011
2015-031
2015-042
2015-052
2015-082
2015-091
2015-111
2016-021
2016-032
2016-041
2016-051
2016-061
2016-1012
2017-091

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.